After Structure Therapeutics (GPCR) released pivotal topline data from the Phase 2b ACCESS program, H.C. Wainwright argues that the clean safety profile along with 15.3% placebo-adjusted weight loss at the 240 mg dose shatters the “oral ceiling,” exceeding the roughly 12.4% efficacy benchmark set by Eli Lilly’s (LLY) orforglipron. The firm, which sees the data validating the “bull case” thesis the firm previously outlined, has a Buy rating and $60 price target on Structure shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment
- Structure Therapeutics rises 101.6%
- Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.
- Structure Phase 2 data for aleniglipron look ‘competitive,’ says Morgan Stanley
- Structure Therapeutics rises 97.3%